Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 6/20 | 0.43 |
| ▸ | FABP7 | O15540 | 4/20 | 0.43 |
| ▸ | FABP3 | P05413 | 3/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17846252 | 1.00 | GRIA4 (0.47) | GRIA4CYP3A4CYP2C19FABP5FABP7 | |
| SCHEMBL17846250 | 1.00 | GRIA4 (0.47) | GRIA4CYP3A4CYP2C19FABP5FABP7 | |
| SCHEMBL1977211 | 0.75 | CHRNB2 (0.46) | HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL6977004 | 0.75 | CHRNB2 (0.46) | HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL1977210 | 0.75 | CHRNB2 (0.46) | HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL19368106 | 0.74 | KDM4E (0.37) | GRIA4CYP3A4CYP2C19KDM4EMAPT | |
| SCHEMBL7274841 | 0.73 | FABP5 (0.57) | GRIA4FABP5FABP7FABP3KDM4E | |
| SCHEMBL14779748 | 0.73 | ACHE (0.37) | — | |
| SCHEMBL14671354 | 0.73 | ACHE (0.37) | — | |
| SCHEMBL22547094 | 0.73 | FABP5 (0.49) | FABP5FABP7FABP3TACR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233858-B1 | ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| US-9884048-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| EP-3233858-A1 | ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170266167-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| WO-2016100050-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016095089-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266167-A1 | ERK INHIBITORS | MAPK1, MAPK3, MAPK6 | GRIA4 3270/4885CYP3A4 776/4885CYP2C19 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.